23 May 2013
Keywords: gsk, cervarix, effective, ph, iii, study, interim
Article | 09 July 2007
An interim analysis of data from a Phase III trial of GlaxoSmithkline's cervical cancer vaccine candidate Cervarix indicates that it ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 July 2007
22 May 2013
© 2013 thepharmaletter.com